Revenue: As of FY2025 Q2, the actual value is USD 266.1 M, beating the estimate of USD 263.39 M.EPS: As of FY2025 Q2, the actual value is USD 0.1, missing the estimate of USD 0.11.EBIT: As of FY2025 Q2, the actual value is USD 8 M.<h3>Home Health Segment</h3><ul><li>Net Service Revenue: $205.9 million for Q2 2025, a decrease of 2.0% from $210.2 million in Q2 2024. For the six months ended June 30, 2025, revenue was $406.5 million, a decrease of 4.0% from $423.4 million in the same period of 2024.</li><li>Cost of Service: $107.2 million for Q2 2025, a slight increase of 0.3% from $106.9 million in Q2 2024. For the six months ended June 30, 2025, cost was $210.6 million, a decrease of 2.9% from $216.8 million in the same period of 2024.</li><li>Segment Adjusted EBITDA: $39.3 million for Q2 2025, a decrease of 11.1% from $44.2 million in Q2 2024. For the six months ended June 30, 2025, EBITDA was $77.6 million, a decrease of 11.2% from $87.4 million in the same period of 2024.</li></ul><h3>Hospice Segment</h3><ul><li>Net Service Revenue: $60.2 million for Q2 2025, an increase of 19.4% from $50.4 million in Q2 2024. For the six months ended June 30, 2025, revenue was $119.5 million, an increase of 20.0% from $99.6 million in the same period of 2024.</li><li>Cost of Service: $28.3 million for Q2 2025, an increase of 13.7% from $24.9 million in Q2 2024. For the six months ended June 30, 2025, cost was $55.1 million, an increase of 12.0% from $49.2 million in the same period of 2024.</li><li>Segment Adjusted EBITDA: $14.0 million for Q2 2025, an increase of 53.8% from $9.1 million in Q2 2024. For the six months ended June 30, 2025, EBITDA was $29.0 million, an increase of 59.3% from $18.2 million in the same period of 2024.</li></ul><h3>Cash Flow</h3><ul><li>Operating Cash Flow: $28.5 million for the six months ended June 30, 2025, compared to $26.9 million in the same period of 2024.</li><li>Investing Cash Flow: $19.0 million provided by investing activities for the six months ended June 30, 2025, primarily from the sale of an investment.</li><li>Financing Cash Flow: $38.9 million used in financing activities for the six months ended June 30, 2025, primarily due to debt repayments.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: The company plans to benefit from improved pricing under the Credit Agreement and pursue acquisitions earlier than anticipated, following the end of the Covenant Adjustment Period on May 9, 2025.</li><li>Non-Core Business: The company closed or consolidated seven Home Health and four Hospice branches in the first half of 2025 as part of performance-based branch closures.</li><li>Outlook: The company is actively engaged in advocacy efforts in response to the proposed 2026 Home Health Rule, which could result in a significant reduction in reimbursement rates if finalized as proposed.</li></ul>

Enhabit Home Health & Hospice | 10-Q: FY2025 Q2 Revenue Beats Estimate at USD 266.1 M